Screener
Maze Therapeutics MAZE Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Maze Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: Maze Therapeutics’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:48 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344903
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized as of June 30, 2026 and December 31, 2025; no shares issued and outstanding as of June 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.001 par value; 500,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 55,504,574 and 49,335,551 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively; 10,372 shares subject to repurchase as of June 30, 2026 and December 31, 2025 | 56 | 49 |
| Additional paid-in-capital | 1,011,985 | 844,354 |
| Accumulated other comprehensive (loss) income | (435) | 110 |
| Accumulated deficit | (558,482) | (489,547) |
| Total stockholders’ equity | 453,124 | 354,966 |
| Total liabilities and stockholders’ equity | $531,625 | $397,127 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Maze Therapeutics's total liabilities & equity?
- Maze Therapeutics (MAZE) reported total liabilities & equity of $531.63M in Q2 2026.
- How has Maze Therapeutics's total liabilities & equity changed year-over-year?
- Maze Therapeutics's total liabilities & equity increased by 75.2% year-over-year, from $303.52M to $531.63M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about Maze Therapeutics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude